Broncus Holding Corp (2216) Fair Value & Analysis
Healthcare · HK · Market cap HK$369M
Fair value as of: Aug 13, 2026
From 1 valuation models · updated 3 days ago
Share price −20.1% over the past month.
Below-average quality, and screening another 61% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (HK$0.3000). The favourable scenario is already priced in.
- Weak quality (39/100) and above fair value at the same time, the margin of safety is missing on both counts.
- The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
- A fairly wide model range (HK$0.1600 to HK$0.3000) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
59‑month range HK$0.4600 – HK$15.10 · fair‑value band HK$0.1600 – HK$0.3000 · the HK$0.6150 price screens above the HK$0.2400 fair value. Dashed = 300-day average. As of Aug 13, 2026.
Analysis
Broncus Holding Corp (2216) currently trades at HK$0.6150, while our model-based Fair Value estimate is HK$0.2400, implying the stock looks roughly 61.0% overvalued today. The Quality Score stands at 39/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).
Trailing-twelve-month revenue stands at HK$174K. Revenue declined 55.4% year over year. It earns a return on equity of -11.2%. The balance sheet holds a net cash position of HK$31.9M. Fundamentals as of Aug 13, 2026
Our scenario range runs from HK$0.1600 (bear case) to HK$0.3000 (bull case); at HK$0.6150, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. For context, the median of 10 Healthcare peers we cover trades at -33% fair-value upside, at -61%, 2216 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 1 models by family
Notify me when 2216 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 40 · Market factors (momentum, volatility) 8
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Broncus Holding Corporation, a medical device company, focuses on the development and commercialization of interventional pulmonology medical devices in China and internationally.
Full company description
Broncus Holding Corporation, a medical device company, focuses on the development and commercialization of interventional pulmonology medical devices in China and internationally. The company offers InterVapor, a thermal vapor treatment system to treat chronic obstructive pulmonary disease (COPD); BroncAblate Radiofrequency Ablation System, a transbronchial interventional treatment product for lung cancer; BroncTarget Targeted Lung Denervation (TLD) Radiofrequency Ablation System for the treatment of acute COPD exacerbation management; H-Marker, a pulmonary surgical marker that can be used to mark the location of the lung nodule for positioning during surgical pneumonectomy; Mist Fountain, a disposable nebulizing micro-catheter for endoscope used for airway anaesthesia, precise antibacterial and anti-inflammatory, tuberculosis drug delivery, phlegm reduction and elimination, thoracic surgery staining location, etc.; and BroncTru, a disposable transbronchoscopic dilatation catheter. It also provides navigation products, such as LungPoint Virtual Bronchoscopic Navigation, a computer-assisted image-based navigation software system; LungPoint Plus/Archimedes Lite, a real-time navigation within the airways for lung biopsy and other procedures; and LungPro System, an archimedes system. In addition, the company offers diagnosis products, such as FleXNeedle, a multipurpose biopsy needle; Archimedes Sheath, a sterile single-use tube that provides a working channel during a bronchoscopic procedure; Archimedes Dilation Balloon, a sterile single-use flexible tube with a balloon at or near the distal tip that is inserted through the bronchoscope or sheath, and for used to dilate the target lung tissue of the bronchial tree; BioStarNeedle, a single use ultrasound-guided needle for retrieval of tissue samples; and Steerable Sheath, a steerable sheath adjustment handle and a working channel. The company was incorporated in 2012 and is headquartered in Hangzhou, China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Broncus Holding Corp reported revenue of HK$174K in FY2025 versus HK$10.9M in FY2021, a compound −64.4%/yr. Reported net income was −HK$17.9M in FY2025.
2216 screens 61% overvalued. Compare with Abbott Laboratories, →
Peer Group
Medical Devices · 350 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Devices median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | $110.91 | $74.79 | -33% |
| Stryker Corporation SYK | $347.21 | $186.28 | -46% |
| Medtronic plc MDT | $90.76 | $65.57 | -28% |
| Boston Scientific Corporation BSX | $51.42 | $38.44 | -25% |
| Edwards Lifesciences Corporation EW | $93.05 | $41.02 | -56% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥153.60 | ¥147.63 | -4% |
| Shanghai United Imaging Healthcare Co 688271 | ¥110.50 | ¥43.60 | -61% |
| Demant A/S DEMANT | kr 289.60 | kr 161.17 | -44% |
| Getinge AB GETIB | kr 239.30 | kr 192.14 | -20% |
| Sectra AB SECTB | kr 280.00 | kr 66.81 | -76% |
Compare Broncus Holding Corp with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Broncus Holding Corp (2216) overvalued or undervalued?
What is the fair value of 2216?
What is the quality score of 2216?
What is the revenue of Broncus Holding Corp (2216)?
What is the net profit margin of 2216?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Broncus Holding Corp and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.